Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis

被引:12
|
作者
Zhang, Haiguang [1 ]
Ge, Junbo [1 ]
Hong, Huanyu [1 ]
Bi, Lili [2 ]
Sun, Zhengwen [1 ]
机构
[1] Yantaishan Hosp, 91 Jiefang Rd, Yantai 264000, Shandong, Peoples R China
[2] Yeda Hosp, Yantai 264000, Shandong, Peoples R China
来源
关键词
ERCC1; ERCC2; Chemotherapy response; Polymorphism; Meta-analysis; FILE-DRAWER PROBLEM; MOLECULAR PATHOGENESIS; SURVIVAL; PATHWAY; VARIABILITY; STRATEGIES; CANCER; GLIOMA; RISK; AGE;
D O I
10.1186/s12957-017-1142-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There existed controversies about the association between the response to chemotherapy for osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1 and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association. Method: We searched multiple databases for literature retrieval including the PubMED (1966 similar to 2017), Embase (1980 similar to 2017), and the Web of science (1945 similar to 2017). The overall odds ratios(OR) and their corresponding 95% confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic models. Results: From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant association was detected between the chemotherapy response and the polymorphism under all three models (dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003), and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181 polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all three models. Conclusions: Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793 polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793 polymorphism were more suitable for chemotherapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
    Xu, Qiang
    Zhang, Zuofu
    Sun, Weixue
    Hu, Baiqiang
    [J]. MAMMALIAN GENOME, 2017, 28 (5-6) : 227 - 233
  • [22] Polymorphisms of DNA repair genes:: ERCC1 G19007A and ERCC2/XPD C22541A in a northeastern Chinese population
    Yin, JY
    Li, JC
    Vogel, U
    Wang, HW
    [J]. BIOCHEMICAL GENETICS, 2005, 43 (9-10) : 543 - 548
  • [23] Polymorphisms of DNA Repair Genes: ERCC1 G19007A and ERCC2/XPD C22541A in a Northeastern Chinese Population
    Jiaoyang Yin
    Jicheng Li
    Ulla Vogel
    Huiwen Wang
    [J]. Biochemical Genetics, 2005, 43 : 543 - 548
  • [24] Polymorphisms in the nucleotide excision repair genes ERCC1 and ERCC2 and association with response and prognosis in neoadjuvant treated gastric cancer patients
    Henningsen, N.
    Ott, K.
    Becker, K.
    Boulesteix, A. L.
    Lordick, F.
    Siewert, J. R.
    Hoefler, H.
    Keller, G.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (05) : 254 - 254
  • [25] Association of ERCC1 C8092A and ERCC2 Lys751Gln Polymorphisms with the Risk of Glioma: A Meta-Analysis
    Xin, Yu
    Hao, Shuyu
    Lu, Jiapeng
    Wang, Qianyi
    Zhang, Liwei
    [J]. PLOS ONE, 2014, 9 (04):
  • [26] GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
    Li, Hui-Yan
    Ge, Xin
    Huang, Guang-Ming
    Li, Kai-Yu
    Zhao, Jing-Quan
    Yu, Xi-Miao
    Bi, Wen-Si
    Wang, Yu-Lin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3465 - 3469
  • [27] Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy
    Mo, Juanmei
    Luo, Min
    Cui, Jiandong
    Zhou, Shaozhang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15065 - 15071
  • [28] ERCC1 and ERCC2 polymorphisms predict the clinical outcomes of oxaliplatin-based adjuvant chemotherapy in colorectal cancer
    Shi, Lei
    Wang, Ran
    Wu, Wen-ming
    Huang, Yi-fei
    [J]. AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (32): : 2429 - 2432
  • [29] Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
    D Caronia
    A Patiño-García
    R L Milne
    M Zalacain-Díez
    G Pita
    M R Alonso
    L T Moreno
    L Sierrasesumaga-Ariznabarreta
    J Benítez
    A González-Neira
    [J]. The Pharmacogenomics Journal, 2009, 9 : 347 - 353
  • [30] Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
    Caronia, D.
    Patino-Garcia, A.
    Milne, R. L.
    Zalacain-Diez, M.
    Pita, G.
    Alonso, M. R.
    Moreno, L. T.
    Sierrasesumaga-Ariznabarreta, L.
    Benitez, J.
    Gonzalez-Neira, A.
    [J]. PHARMACOGENOMICS JOURNAL, 2009, 9 (05): : 347 - 353